Search Results

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (Protocol Version 17.0) MOA: ART0380 selectively targets and inhibits ATR activity and blocks the downstream phosphorylation of the serine/threonine…

What Black Women Need to Know About Breast Cancer Risk A healthcare provider holding a tablet speaks with a patient seated on an exam table in a medical office Breast cancer is the most commonly diagnosed cancer in Black women. And while Black women have an overall lower breast cancer incidence rate than white women,…

Jody has worked as a nurse practitioner in breast surgical oncology with Maryland Oncology since 2021. She graduated with her Associates of Science degree in nursing in 2006 followed by her BSN in 2008. She completed her undergraduate studies in Pennsylvania and her Masters of Science degree in nursing at George Washington University. The majority…

Adv solid tumors inclovarian, endometrial, cervix Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors MOA: Rina-S is an FRα-directed antibody-drug conjugate with an exatecan payload (topoisomerase I inhibitor) Key Eligibility Criteria: Histologically or cytologically confirmed metastatic or unresectable solid tumor (detailed below) All cohorts require measurable disease per RECIST…

SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression (J3M-MC-JZQB) MOA: LY3537982…